Vagus Nerve Stimulation May Ease RA Symptoms

Share this content:
Vagus Nerve Stimulation May Ease RA Symptoms
Vagus Nerve Stimulation May Ease RA Symptoms

TUESDAY, July 12, 2016 (HealthDay News) -- Electronic stimulation of the vagus nerve may help ease symptoms of rheumatoid arthritis (RA), according to a study published online July 5 in the Proceedings of the National Academy of Sciences.

Kevin Tracey, M.D., president of the Feinstein Institute for Medical Research in Manhasset, N.Y., and colleagues implanted a vagus nerve stimulation (VNS) device in 17 patients with RA. Seven were in the earlier stages of the disease and had not responded to methotrexate. The rest had more advanced disease and had failed to improve after trying at least two biologic drugs.

Six weeks after the VNS devices were implanted, most of the patients were improving. The researchers found that 71.4 percent had at least a 20 percent improvement in their symptoms -- including a reduction in the number of tender, swollen joints. In the group with early-stage RA, 57.1 percent had at least a 50 percent improvement; that was true for 28.6 percent of patients with more advanced disease. Blood levels of tumor necrosis factor, interleukin-1β, and interleukin-6 declined.

"This first-in-class study supports a conceptual framework for further studies of electronic medical devices in diseases currently treated with drugs," the authors write. "Larger clinical trials in RA can be designed and powered to assess clinical efficacy, but our findings encourage pursuing this strategy."

SetPoint Medical, a company that is developing neuromodulation therapies for RA and other diseases, funded the study. Tracey is a consultant to the company, and several of his co-researchers are SetPoint employees.

Full Text

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Approves Zejula for Certain Female Cancers

FDA Approves Zejula for Certain Female Cancers

PARP inhibitor may help fight tumors affecting the ovaries, fallopian tubes, or peritoneum

USPSTF: Evidence Lacking for Celiac Dz Screen in Asymptomatic

USPSTF: Evidence Lacking for Celiac Dz Screen in ...

Insufficient evidence for weighing benefits, harms of screening for celiac disease in asymptomatic

Lap, Abdominal Hysterectomy Equal for Early Endometrial CA

Lap, Abdominal Hysterectomy Equal for Early Endometrial CA

Equivalent disease-free survival at 4.5 years for stage I endometrial cancer with TAH, TLH

is free, fast, and customized just for you!

Already a member?

Sign In Now »